4SC AG IPO year
What is the IPO year of 4SC AG?
The IPO year of 4SC AG is 2005
What is the definition of IPO year?
Initial public offering is a type of public offering in which shares of a company usually are sold to institutional investors that in turn, sell to the general public, on a securities exchange, for the first time.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO year of companies in the Health Care sector on XETRA compared to 4SC AG
What does 4SC AG do?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Companies with ipo year similar to 4SC AG
- Rurelec PLC has IPO year of 2004
- Kona Bay Technologies has IPO year of 2004
- FE Investments has IPO year of 2004
- JBF Industries has IPO year of 2004
- Indiabulls Ventures has IPO year of 2004
- Alexion Pharmaceuticals has IPO year of 2004
- 4SC AG has IPO year of 2005
- Compass Diversified has IPO year of 2006
- Green Plains Inc has IPO year of 2006
- Catalyst Pharmaceuticals Inc has IPO year of 2006
- Greatland Gold Plc has IPO year of 2006
- Capital Environment has IPO year of 2006
- Athena Resources has IPO year of 2006